{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T01:07:19Z","timestamp":1790298439952,"version":"4.1.0"},"reference-count":39,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2022,8,16]]},"abstract":"<jats:sec id=\"ab-joi220084-4\"><jats:title>Importance<\/jats:title><jats:p>The incidence of arterial thromboembolism and venous thromboembolism in persons with COVID-19 remains unclear.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi220084-5\"><jats:title>Objective<\/jats:title><jats:p>To measure the 90-day risk of arterial thromboembolism and venous thromboembolism in patients hospitalized with COVID-19 before or during COVID-19 vaccine availability vs patients hospitalized with influenza.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi220084-6\"><jats:title>Design, Setting, and Participants<\/jats:title><jats:p>Retrospective cohort study of 41\u202f443 patients hospitalized with COVID-19 before vaccine availability (April-November 2020), 44\u202f194 patients hospitalized with COVID-19 during vaccine availability (December 2020-May 2021), and 8269 patients hospitalized with influenza (October 2018-April 2019) in the US Food and Drug Administration Sentinel System (data from 2 national health insurers and 4 regional integrated health systems).<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi220084-7\"><jats:title>Exposures<\/jats:title><jats:p>COVID-19 or influenza (identified by hospital diagnosis or nucleic acid test).<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi220084-8\"><jats:title>Main Outcomes and Measures<\/jats:title><jats:p>Hospital diagnosis of arterial thromboembolism (acute myocardial infarction or ischemic stroke) and venous thromboembolism (deep vein thrombosis or pulmonary embolism) within 90 days. Outcomes were ascertained through July 2019 for patients with influenza and through August 2021 for patients with COVID-19. Propensity scores with fine stratification were developed to account for differences between the influenza and COVID-19 cohorts. Weighted Cox regression was used to estimate the adjusted hazard ratios (HRs) for outcomes during each COVID-19 vaccine availability period vs the influenza period.<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi220084-9\"><jats:title>Results<\/jats:title><jats:p>A total of 85\u202f637 patients with COVID-19 (mean age, 72 [SD, 13.0] years; 50.5% were male) and 8269 with influenza (mean age, 72 [SD, 13.3] years; 45.0% were male) were included. The 90-day absolute risk of arterial thromboembolism was 14.4% (95% CI, 13.6%-15.2%) in patients with influenza vs 15.8% (95% CI, 15.5%-16.2%) in patients with COVID-19 before vaccine availability (risk difference, 1.4% [95% CI, 1.0%-2.3%]) and 16.3% (95% CI, 16.0%-16.6%) in patients with COVID-19 during vaccine availability (risk difference, 1.9% [95% CI, 1.1%-2.7%]). Compared with patients with influenza, the risk of arterial thromboembolism was not significantly higher among patients with COVID-19 before vaccine availability (adjusted HR, 1.04 [95% CI, 0.97-1.11]) or during vaccine availability (adjusted HR, 1.07 [95% CI, 1.00-1.14]). The 90-day absolute risk of venous thromboembolism was 5.3% (95% CI, 4.9%-5.8%) in patients with influenza vs 9.5% (95% CI, 9.2%-9.7%) in patients with COVID-19 before vaccine availability (risk difference, 4.1% [95% CI, 3.6%-4.7%]) and 10.9% (95% CI, 10.6%-11.1%) in patients with COVID-19 during vaccine availability (risk difference, 5.5% [95% CI, 5.0%-6.1%]). Compared with patients with influenza, the risk of venous thromboembolism was significantly higher among patients with COVID-19 before vaccine availability (adjusted HR, 1.60 [95% CI, 1.43-1.79]) and during vaccine availability (adjusted HR, 1.89 [95% CI, 1.68-2.12]).<\/jats:p><\/jats:sec><jats:sec id=\"ab-joi220084-10\"><jats:title>Conclusions and Relevance<\/jats:title><jats:p>Based on data from a US public health surveillance system, hospitalization with COVID-19 before and during vaccine availability, vs hospitalization with influenza in 2018-2019, was significantly associated with a higher risk of venous thromboembolism within 90 days, but there was no significant difference in the risk of arterial thromboembolism within 90 days.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jama.2022.13072","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T15:03:36Z","timestamp":1660662216000},"page":"637","source":"Crossref","is-referenced-by-count":84,"title":["Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients"],"prefix":"10.1001","volume":"328","author":[{"suffix":"III","given":"Vincent","family":"Lo Re","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, and Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah K.","family":"Dutcher","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John G.","family":"Connolly","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Perez-Vilar","sequence":"additional","affiliation":[{"name":"Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean M.","family":"Carbonari","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, and Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terese A.","family":"DeFor","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Bloomington, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Djeneba Audrey","family":"Djibo","sequence":"additional","affiliation":[{"name":"CVS Health Clinical Trial Services, Blue Bell, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura B.","family":"Harrington","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Washington Health Research Institute, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Hou","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Hennessy","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, and Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Hubbard","sequence":"additional","affiliation":[{"name":"Center for Clinical Epidemiology and Biostatistics, Center for Pharmacoepidemiology Research and Training, and Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria E.","family":"Kempner","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer L.","family":"Kuntz","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Northwest Center for Health Research, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheryl N.","family":"McMahill-Walraven","sequence":"additional","affiliation":[{"name":"CVS Health Clinical Trial Services, Blue Bell, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolene","family":"Mosley","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamala A.","family":"Pawloski","sequence":"additional","affiliation":[{"name":"HealthPartners Institute, Bloomington, Minnesota"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew B.","family":"Petrone","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allyson M.","family":"Pishko","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meighan Rogers","family":"Driscoll","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia A.","family":"Steiner","sequence":"additional","affiliation":[{"name":"Kaiser Permanente Colorado Institute for Health Research, Aurora"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunping","family":"Zhou","sequence":"additional","affiliation":[{"name":"Humana Healthcare Research Inc, Louisville, Kentucky"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noelle M.","family":"Cocoros","sequence":"additional","affiliation":[{"name":"Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Healthcare Institute, Boston, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"17","key":"joi220084r1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2007575","article-title":"Coagulopathy and antiphospholipid antibodies in patients with COVID-19.","volume":"382","author":"Zhang","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"joi220084r2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood.2020006520","article-title":"COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection.","volume":"136","author":"Al-Samkari","year":"2020","journal-title":"Blood"},{"issue":"6","key":"joi220084r3","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1055\/s-0040-1710018","article-title":"COVID-19\u2013related severe hypercoagulability in patients admitted to intensive care unit for acute respiratory failure.","volume":"120","author":"Spiezia","year":"2020","journal-title":"Thromb Haemost"},{"issue":"23","key":"joi220084r4","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1182\/blood.2020006000","article-title":"COVID-19 and its implications for thrombosis and anticoagulation.","volume":"135","author":"Connors","year":"2020","journal-title":"Blood"},{"key":"joi220084r5","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.thromres.2020.04.013","article-title":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19.","volume":"191","author":"Klok","year":"2020","journal-title":"Thromb Res"},{"issue":"24","key":"joi220084r6","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMc2010419","article-title":"Clinical characteristics of COVID-19 in New York City.","volume":"382","author":"Goyal","year":"2020","journal-title":"N Engl J Med"},{"issue":"5","key":"joi220084r7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.7326\/M20-2566","article-title":"Pulmonary arterial thrombosis in COVID-19 with fatal outcome: results from a prospective, single-center, clinicopathologic case series.","volume":"173","author":"Lax","year":"2020","journal-title":"Ann Intern Med"},{"key":"joi220084r8","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.thromres.2020.04.024","article-title":"Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.","volume":"191","author":"Lodigiani","year":"2020","journal-title":"Thromb Res"},{"issue":"8","key":"joi220084r9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1111\/jth.14888","article-title":"Incidence of venous thromboembolism in hospitalized patients with COVID-19.","volume":"18","author":"Middeldorp","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"5","key":"joi220084r10","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.10478","article-title":"Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19).","volume":"3","author":"Nahum","year":"2020","journal-title":"JAMA Netw Open"},{"issue":"21","key":"joi220084r11","doi-asserted-by":"publisher","first-page":"4925","DOI":"10.3390\/jcm10214925","article-title":"Venous thromboembolism in COVID-19 compared to non\u2013COVID-19 cohorts: a systematic review with meta-analysis.","volume":"10","author":"Tufano","year":"2021","journal-title":"J Clin Med"},{"issue":"4","key":"joi220084r12","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1056\/NEJMoa1702090","article-title":"Acute myocardial infarction after laboratory-confirmed influenza infection.","volume":"378","author":"Kwong","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"joi220084r13","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1002\/acn3.545","article-title":"Influenza-like illness as a trigger for ischemic stroke.","volume":"5","author":"Boehme","year":"2018","journal-title":"Ann Clin Transl Neurol"},{"issue":"2","key":"joi220084r14","doi-asserted-by":"publisher","first-page":"e14","DOI":"10.1093\/cid\/ciq125","article-title":"Pandemic H1N1 influenza infection and vascular thrombosis.","volume":"52","author":"Bunce","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"4","key":"joi220084r15","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofw214","article-title":"H1N1-induced venous thromboembolic events? results of a single-institution case series.","volume":"3","author":"Dimakakos","year":"2016","journal-title":"Open Forum Infect Dis"},{"key":"joi220084r16","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1002\/pds.2336","article-title":"Design considerations, architecture, and use of the mini-Sentinel distributed data system.","volume":"21","author":"Curtis","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"joi220084r17","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/pds.5240","article-title":"A COVID-19\u2013ready public health surveillance system: the Food and Drug Administration\u2019s Sentinel System.","volume":"30","author":"Cocoros","year":"2021","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"24","key":"joi220084r20","doi-asserted-by":"publisher","first-page":"544","DOI":"10.15585\/mmwr.mm6824a3","article-title":"Update: influenza activity in the United States during the 2018-19 season and composition of the 2019-20 influenza vaccine.","volume":"68","author":"Xu","year":"2019","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"joi220084r21","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1002\/pds.3310","article-title":"Validation of acute myocardial infarction in the Food and Drug Administration\u2019s mini-Sentinel program.","volume":"22","author":"Cutrona","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"joi220084r22","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1002\/pds.4398","article-title":"Chart validation of inpatient ICD-9-CM administrative diagnosis codes for acute myocardial infarction (AMI) among intravenous immune globulin (IGIV) users in the Sentinel distributed database.","volume":"27","author":"Ammann","year":"2018","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"joi220084r23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1002\/pds.1924","article-title":"Validation of claims-based diagnostic and procedure codes for cardiovascular and gastrointestinal serious adverse events in a commercially-insured population.","volume":"19","author":"Wahl","year":"2010","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"joi220084r24","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1002\/pds.1518","article-title":"Validation of ICD-9 codes with a high positive predictive value for incident strokes resulting in hospitalization using Medicaid health data.","volume":"17","author":"Roumie","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"joi220084r25","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.vaccine.2015.09.087","article-title":"Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among US females.","volume":"34","author":"Yih","year":"2016","journal-title":"Vaccine"},{"issue":"8","key":"joi220084r26","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000009960","article-title":"Chart validation of inpatient International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) administrative diagnosis codes for venous thromboembolism (VTE) among intravenous immune globulin (IGIV) users in the Sentinel distributed database.","volume":"97","author":"Ammann","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"7","key":"joi220084r27","doi-asserted-by":"publisher","first-page":"749","DOI":"10.1016\/j.jclinepi.2010.10.004","article-title":"A combined comorbidity score predicted mortality in elderly patients better than existing scores.","volume":"64","author":"Gagne","year":"2011","journal-title":"J Clin Epidemiol"},{"issue":"7497","key":"joi220084r29","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/bmj.330.7497.960","article-title":"Reader\u2019s guide to critical appraisal of cohort studies, 2: assessing potential for confounding.","volume":"330","author":"Mamdani","year":"2005","journal-title":"BMJ"},{"issue":"2","key":"joi220084r30","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score\u2013based fine stratification approach for confounding adjustment when exposure is infrequent.","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"key":"joi220084r31","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"joi220084r32","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1177\/0962280219869742","article-title":"Inverse probability weighted Cox model in multi-site studies without sharing individual-level data.","volume":"29","author":"Shu","year":"2020","journal-title":"Stat Methods Med Res"},{"issue":"4","key":"joi220084r33","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value.","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"issue":"8","key":"joi220084r34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1001\/jama.2020.13372","article-title":"Thrombosis in hospitalized patients with COVID-19 in a New York City health system.","volume":"324","author":"Bilaloglu","year":"2020","journal-title":"JAMA"},{"issue":"11","key":"joi220084r35","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/jamaneurol.2020.2730","article-title":"Risk of ischemic stroke in patients with coronavirus disease 2019 (COVID-19) vs patients with influenza.","volume":"77","author":"Merkler","year":"2020","journal-title":"JAMA Neurol"},{"issue":"10234","key":"joi220084r36","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(20)30937-5","article-title":"Endothelial cell infection and endotheliitis in COVID-19.","volume":"395","author":"Varga","year":"2020","journal-title":"Lancet"},{"issue":"6","key":"joi220084r37","doi-asserted-by":"publisher","first-page":"e438","DOI":"10.1016\/S2352-3026(20)30145-9","article-title":"Coagulation abnormalities and thrombosis in patients with COVID-19.","volume":"7","author":"Levi","year":"2020","journal-title":"Lancet Haematol"},{"issue":"2","key":"joi220084r38","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2015432","article-title":"Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19.","volume":"383","author":"Ackermann","year":"2020","journal-title":"N Engl J Med"},{"issue":"1","key":"joi220084r39","doi-asserted-by":"publisher","first-page":"5749","DOI":"10.1038\/s41467-020-19478-2","article-title":"Collider bias undermines our understanding of COVID-19 disease risk and severity.","volume":"11","author":"Griffith","year":"2020","journal-title":"Nat Commun"},{"key":"joi220084r19","author":"US Department of Health and Human Services"},{"key":"joi220084r18","unstructured":"Rosati? K, Jorgensen? N, Soliz? M, Evans? BJ. Sentinel Initiative principles and policies: HIPAA and Common Rule compliance in the Sentinel Initiative. Accessed October 31, 2021. https:\/\/www.sentinelinitiative.org\/sites\/default\/files\/communications\/publications-presentations\/HIPAA-Common-Rule-Compliance-in-Sentinel-Initiative.pdf"},{"key":"joi220084r28","doi-asserted-by":"crossref","unstructured":"US Food and Drug Administration. Master protocol development: COVID-19 natural history. Accessed October 27, 2021. https:\/\/www.sentinelinitiative.org\/sentinel\/methods\/master-protocol-development-covid-19-natural-history","DOI":"10.1001\/jamaoncol.2020.4975"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2795268\/jama_lo_re_2022_oi_220084_1728684489.81372.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,14]],"date-time":"2024-10-14T15:01:36Z","timestamp":1728918096000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2795268"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,16]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,8,16]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2022.13072","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,16]]}}}